Topas Therapeutics GmbH is a clinical-stage biotechnology company focused on developing novel treatments in areas where patients are in need of more effective options, including autoimmune diseases, allergies and anti-drug immune responses. The Topas Particle Conjugates platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. The Company has several proprietary programs: Lead product candidate TPM203 is advancing through initial clinical testing in pemphigus vulgaris, an orphan disease. Our second program, TPM502, will soon enter a clinical trial in celiac disease. Topas has several other proprietary programs, including in rheumatoid arthritis, Type I diabetes and multiple sclerosis, in pre-clinical development. Other programs are in the area of anti-drug immune responses, such as in gene therapy and with anti-drug antibodies. Our pre-clinical programs are available for partnering, and with the power of our platform, new indications can quickly be developed and brought into clinical testing. Investors in privately held Topas are: BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III.